Viz.ai and Nico Collaborate on Intracerebral Hemorrhage Treatment

April 17, 2024—Viz.ai announced a collaboration with Nico Corporation for the treatment of patients with intracerebral hemorrhage (ICH).

According to the company, Viz.ai’s artificial intelligence- (AI-) powered technology is used to detect suspected disease earlier and receive accurate volume measurements of brain bleeds to assess the severity of cases. Nico’s BrainPath provides early and safe access to the brain and its Myriad technology allows maximal evacuation of the clot.

The company stated that its AI-powered Viz ICH Plus module allows hospital and health systems to automate the process of identifying, labeling, and quantifying the volume of segmentable brain structures on noncontrast CT images.

The company noted that the results of the ENRICH trial demonstrated that early minimally invasive parafascicular surgery intervention—or MIPS—using Nico’s BrainPath and Myriad technologies is safe and superior for ICH treatment compared to guideline-based medical management alone, the current standard of care. The ENRICH trial showed improved functional and economic outcomes for ICH.

Gustavo Pradilla, MD, et al recently published the ENRICH findings online in The New England Journal of Medicine. In March 2023, Jonathan J. Ratcliff, MD, et al published “Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH): Study Protocol for a Multi-Centered Two-Arm Randomized Adaptive Trial” in Frontiers in Neurology.